A micro-cap stock which boasts of a virtual monopoly, moat, high RoE, reasonable valuations, growth prospects etc has attracted the attention of ace stock pickers and all are recommending a buy with the promise that hefty gains can be harvested from the stock
The omission to home in on Billionaire Prem Watsa’s no-brainer stock pick despite a 24×7 vigil has cost us dearly and exposed severe chinks in our armour
ICICI-Direct has recommended a few top-quality Large-Cap & Mid-Cap Stocks for investment
Edelweiss has recommended a Model Portfolio of seven top-quality mid-cap stocks for investment
When powerhouse stocks with impeccable management integrity, sound business model, debt-free status go into a downturn owing to macro issues, they should be bought aggressively. This is the staunch belief of Ashish Chugh and Daljeet Kohli, both of whom have mastered the fine art of finding winning stocks
Dharmesh Kant, now with Motilal Oswal, is diligently discharging his responsibility of identifying winning stocks and recommending them to us. He has now homed in on a top-quality stock which stands to benefit from the demand for specialty chemicals and pharmaceuticals
Kenneth Andrade conducted a brilliant analysis of his latest stock pick. However, he lost sight of the fact that the Government calls the shots in the sector and is loath to let the corporate prosper at the cost of the impoverished farmers
Basant Maheshwari’s stock picking mastery has enabled him to pocket mega gains from a “Rajnikant” style stock even as his PMS is growing in strength
Rahul Arora of Nirmal Bang has recommended a blue-chip large-cap Pharma stock which has fallen from favour owing to USFDA issues. He claims that profits of the Company can “triple” and that the time is now opportune to buy the stock
Bloomberg has revealed important information relating to the AUM and returns of Prof Sanjay Bakshi’s ValueQuest India Moat Fund
Recent Comments